Expanded Indications For Integra’s Vu aPOD™ Prime Intervertebral Body Fusion Device

In short

Contributing to the flurry of neuro and spinal product announcements timed to coincide with congress season, Integra® LifeSciences Holdings Corporation has proclaimed the FDA’s expanded indication for use of the Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD) in anterior lumbar interbody fusion (ALIF) procedures.

The new stand-alone indication includes four points of fixation, which is composed of two screws and a SpinPlate™

Background

IBDs are designed to help provide stability for spinal fusion after a diseased lumbar disc is surgically removed. They are small, hollow spinal implants that are inserted into the intervertebral space to restore physiological disc height and allow fusion between vertebral bodies. These devices relieve pressure on the nerves and provide positive mechanical stabilisation of the vertebrae. The graft window in the device is packed with bone and provides an environment in which natural bone growth can occur, which then enables fusion of the vertebral segments.

Traditionally, surgeons use supplemental fixation to help hold the IBD in place. However, the Integra® Vu aPOD™ Prime IBD features two zero-profile options utilising two screws or two screws and a SpinPlate™ to help secure the IBD in its functional position, eliminating the need for supplemental fixation implants, and reducing the number of steps and implants required to perform an ALIF procedure.

Physician comments

“The Integra® Vu aPOD™ Prime IBD provides surgeons with an easy and safer approach when compared to other devices that have four points of fixation with four screws, and a very minimally invasive way to provide stability of the anterior lumbar spine, with no additional sharp objects introduced to the outside of the spine,” said Jaideep Chunduri, MD, a design surgeon from Beacon Orthopaedics and Sports Medicine in Cincinnati, Ohio. “It is often difficult to place screws laterally within the lumbar spine. Integra’s SpinPlate™, in conjunction with two screws, enables four-point fixation without significant retraction. Because the SpinPlate™ is also located within the middle of the device, and provides built-in fixation, there is no added risk in terms of blood loss or vascular tissue. ”

Company comments

“Earlier this year the Vu aPOD™ Prime IBD entered its full market release with stand-alone indications,” said Kirt Stephenson, President, U.S. Spine. “We’re pleased that with this additional indication, we can now provide surgeons with multiple fixation options to best meet their patients’ needs.”

 Source: Integra Lifescience Holdings Corporation, Globe Newswire